All the below links and tweets are in English.
取り急ぎ以下貼っておきます。
CSL（豪）の子会社
Pennsylvania Vol.11 (corporations: CSL Behring) / Australia Vol.29
UK Vol.173 (pharmaceutical corporations: Seqirus) / Australia Vol.30
上記リンク内に無い本日までのツイート
CSL #FlashbackFriday – 10 Decades in 10 Weeks
1946 to 1956: CSL is manufacturing polio vaccine, a wide range of human and veterinary vaccines, antisera to some of Australia's most venomous snakes and spiders, insulin, penicillin and a suite of blood products. pic.twitter.com/XXkR5KPiD7— CSL (@CSL) November 5, 2020
https://twitter.com/SamDForever1/status/1325970911258836992
Coronavirus vaccine production begins in Australia before Oxford-AstraZeneca's products last stage of approval @AstraZeneca @csl #Vaccine #Covid19 #Coronavirus https://t.co/U8zKQWp6QX pic.twitter.com/6J6sHNaypJ
— ProTech Recruitment Ltd (@ProTechLtd) November 9, 2020
.@CSL began manufacturing the University of Oxford/AstraZeneca AZD1222 Covid-19 vaccine candidate at its facility in Broadmeadows in northern Melbourne today.https://t.co/xBb64K7DHA#COVID19 #vaccine #manufacturing
— AustralianManufacturingForum (@AuManufacturing) November 9, 2020
Global #biotech company @CSL has commenced the manufacture of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne – a further endorsement for the city’s thriving biotech and #advancedmanufacturing capabilities https://t.co/vb5JAlVy0F pic.twitter.com/dtHis3oOWm
— Invest Victoria (@InvestVictoria) November 9, 2020
.@CSL commences manufacture of @UniofOxford /@AstraZeneca vaccine candidate: https://t.co/6CjpTf2qNL
— AUS Manufacturing (@AustralianM) November 9, 2020
https://twitter.com/DayofImmunology/status/1325371202831962112
A great example of how videos can assist in communicating share plans to employees by Australian company @CSL #EmployeeOwnership #EmployeeOwned https://t.co/drAi6zwle7
— Employee Ownership Australia (@EOwnership) November 6, 2020
This is quite remarkable: you’re looking at the first vial of ‘starting material’ of the @AstraZeneca COVID-19 vaccine in Australia. @CSL will start making millions of doses from tomorrow – in anticipation of final approvals next year. @7NewsMelbourne pic.twitter.com/UkHzZNrAkF
— Blake Johnson (@BlakeJohnson) November 8, 2020
“The #Australian government… said on Thursday [it] will buy 40M #vaccine doses from @Novavax, and 10 million from @Pfizer and @BioNTech_Group… That adds to the 85M doses Australia has already committed to buy from @AstraZeneca and @CSL…” #COVID19 https://t.co/4pe1y0mEWl
— Mark Warner (@MAAWLAW) November 5, 2020
Morning Bell: #ASX200 to gain 0.2% at the open. VIC #COVID19 restrictions have been eased & @CSL is set to produce 30 mil #COVID19Vaccines. #Brexit talks to dominate this week, keep an eye on $LNK & $VUK. Trading ideas: $MQG & $BXB. #ausbiz #belldirect https://t.co/Qb1Xf7JJlo
— Bell Direct (@belldirect) November 8, 2020
Are you debating your holiday plans? Get some expert advice about how to stay safe, especially if you're living with a rare or chronic illness. https://t.co/5iXQVwsaUC
— CSL Behring (@CSLBehring) November 6, 2020
Help raise awareness this November – it's #Alpha1Awareness month – by learning more. It’s a rare hereditary respiratory condition sometimes called genetic #COPD. It’s estimated only 10% of patients are properly diagnosed…could you be one of them? https://t.co/tndZncDf1n
— CSL Behring (@CSLBehring) November 5, 2020
Scientists at #CSLBehring are offering some advice about how to clean up at home and prevent the spread of #COVID19. They tested several cleaning agents, including a commonly available household soap, and found they all killed the virus. https://t.co/LP7GuI673O
— CSL Behring (@CSLBehring) November 5, 2020
Today, the study design for our landmark Phase 3 AEGIS-II trial was published in @AmericanHeartJ Read more about our cardiovascular research program involving #heartattack survivors: https://t.co/WByn9r3ny6 @CMichaelGibson #cardiotwitter pic.twitter.com/go8GivEfAw
— CSL Behring (@CSLBehring) November 5, 2020
One key lesson from the #COVID19 pandemic is the need for global cooperation to develop potential therapeutics. #CSLBehring is proud to collaborate with our partners in the CoVIg-19 Plasma Alliance on a potential treatment. More here: https://t.co/La5JtJmMkp
— CSL Behring (@CSLBehring) November 2, 2020
#NEWS: Both the @US_FDA and @EMA_News have granted orphan drug designation to our investigational therapy for #SickleCellDisease Learn more: https://t.co/aJ36nNJ1JA @GregoryKatoMD pic.twitter.com/VghvWrIBpB
— CSL Behring (@CSLBehring) November 2, 2020
https://twitter.com/CSLBehring/status/1322931444545703938
CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patientshttps://t.co/dcDfXyJNgb@CSLBehring#cardiologist #doctor #cardio #cardiovascular #ECG #HeartNews #healthcare #medicaltechnology
— Cardiology 2.0 (@cardiology_2) November 5, 2020
.@CSLBehring's @johnkthompson60 shares advice on scaling #datascience — making the case for a #COE, building a team from scratch, setting priorities, and more: https://t.co/o5ivCh9qox pic.twitter.com/a49gANEJiA
— Domino Data Lab (@DominoDataLab) November 4, 2020
https://twitter.com/thalassaemiaTIF/status/1325715357408120835
Why is Liverpool the flu jab manufacturing capital of the country? Is this why the mayor is so keen to stay on Johnson's good side? Is there a vaccine contract up for grabs? There are at least three vaccine companies in Speke alone! #KBF #CovidVaccine https://t.co/2VRdszJEF9
— SarcasticSooooooz #JFT96 #KBF #Abetterway (@goldjerrygold1) November 4, 2020
Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020 https://t.co/dPjCGTf2BZ
— IMPharma News (@IMPharmaNews) November 2, 2020
ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
The CoVIg-19 Plasma Alliance (Takeda, @bplplasmallc, @BiotestPlasma, @CSLBehring, @LFB_Group, @OctapharmaGroup, @AdmaBiologics, @BiomedPharmaGC, @sanquin, etc) has begun clinical production of a potential #COVID19 medicine. Help by donating plasma: https://t.co/q6Fe7VvHlG pic.twitter.com/Zcp4aNWpfh
— Takeda (@TakedaPharma) May 18, 2020
Takeda has joined forces with @bplplasmallc, @BiotestPlasma, @CSLBehring, @LFB_Group and @OctapharmaGroup to accelerate a potential treatment option for those at risk of serious complications from #COVID19. https://t.co/8MfTnO7olj pic.twitter.com/wimzKrVyh4
— Takeda (@TakedaPharma) April 23, 2020
Industry alliance brings together Takeda and other world-leading plasma companies, @BPLPlasmaLLC, @BiotestPlasma, @CSLBehring @LFB_Group and Octapharma, to accelerate development of a hyperimmune immunoglobulin medicine in the fight against #COVID19. https://t.co/ok9gZ1r1nf pic.twitter.com/mrpgUDg46l
— Takeda (@TakedaPharma) April 6, 2020
Ashfield proudly provides contact center support for #TheFightisInUs – joining global leaders, @Microsoft, @Takeda, @CSLBehring, @MayoClinic , @AdCouncil, @AmericasBlood in the campaign to collect life-saving #plasma from #COVID19 survivors. Learn more: https://t.co/J4vZzeYrpl pic.twitter.com/NKxwMWLxHl
— Ashfield Healthcare (@AshfieldCM) May 29, 2020
Australian biotech giant @CSL has formed a consortium with Takeda Pharmaceutical Company to develop a potential plasma therapy to fight #coronavirus. Story: https://t.co/TARpXMR76H pic.twitter.com/xNXtkLLd7v
— ManufacturersMonthly (@manmonthly) April 8, 2020
Toby Simon discussing the alliance between major producers of hyper-immune plasma therapies including @CSL_plasma @takeda and othershttps://t.co/fFH7rHJgUT#NewyorkBIO_COVID19
— NewYorkBIO (@newyorkbio) June 25, 2020
@CSLBehring is part of the CoVIg-19 Plasma Alliance that includes Biotest, BPL, LFB, Octapharma, Takeda, ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. @GatesFoundation is providing advisory support. Microsoft is providing technology. https://t.co/ctv0gLJiKI
— NCBIO (@ncbio) May 18, 2020
Biotest, BPL Group, LFB, and Octapharma have joined an alliance formed by CSL Behring and Takeda to develop a potential plasma-derived therapy for treating #COVID-19. https://t.co/yvjUnzLuVP @CSLBehring @TakedaPharma pic.twitter.com/YjtGyPdkQv
— Georgia Bio (@Georgia_Bio) April 6, 2020
CSL teams up with Takeda to create virus plasma treatmenthttps://t.co/S7Z6GXTj3T
— Financial Review (@FinancialReview) April 6, 2020
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL https://t.co/dzdsNLhA5N
— cafepharma (@cafepharma) October 11, 2020
CSL and Takeda have isolated it and refined it into an anti-sera. CSL is the source for the plasma.
Trials begin this summer.https://t.co/nilSD0fo8G— Timothy Gumm (@timothy_gumm) May 13, 2020
Japan approves #remdesivir to treat #COVID19; plus Takeda and CSL's Plasma Alliance will run its globulin trial with NIH, and a trio of Chinese biotechs partnered for an antibody therapy https://t.co/hKOoMUl3QM
— BioCentury (@BioCentury) May 8, 2020
As part of the global response against #COVID19 the #Swiss pharmaceutical company @OctapharmaGroup has joined with Biotest (Germany), BPL (UK), CSL Behring (Australia), Groupe LFB (France) and Takeda Pharma (Japan) to develop treatments. #SwissTechL39https://t.co/UI3zppqkUt
— Swiss Embassy UK (@SwissEmbassyUK) April 16, 2020
‘It’s a humanitarian effort’: Led by Takeda and CSL Behring, a plasma coalition forms to fight #COVID-19. A new, worldwide coalition of plasma companies is seeking to develop and deliver a hyperimmune immunoglobulin therapy for… https://t.co/3HUIA8rTuX pic.twitter.com/LY0FsR10x4
— PIER MARIA FORNASARI (@PierFornasari) April 13, 2020
CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy @themotleyfool #stocks $TAK $CSLLY $EBS https://t.co/Lg69jmchXb
— Paula Schuck (@inkscrblr) April 10, 2020
CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy | NASDAQ https://t.co/uU7dcI4Nkl
— Economic Alliance of Kankakee County (@KankakeeCoEDC) April 9, 2020
quite a news here: big plasma-derived therapies' players (Biotest, Bio Products Laboratory, CSL, LFB, Octapharma and Takeda) join forces to immediately begin developing a non-company specific trademarked polyclonal hyperimmunoglobulin drug against SARS-CoV-2. https://t.co/agJaq44XX1
— Bertrand Delsuc (@BertrandBio) April 6, 2020
Says an organization w/ following roster of sponsors: 2019 Strategic Partners
Gold:
AstraZeneca
GSK
Merck & Co., Inc.
Pfizer Inc.
Sanofi Pasteur
Silver:
Janssen Therapeutics
Medicago Inc.
Bronze:
Seqirus, Inc. USA
Takeda https://t.co/DGLx3Lxfqh— Plum Remson (@PlumRemson) November 10, 2019
Thank you again for our Virtual National Conference Sponsors for their continued support and dedication to the Alpha-1 Community. pic.twitter.com/A6ImAupRSS
— Alpha-1 Foundation (@AlphaFriend) June 29, 2020
Varicella Live Vaccine Market (impact of COVID-19) Demand, Growth and Opportunity 2020| Astellas Pharma Inc., CSL… https://t.co/02vQ6n1fqA >>> https://t.co/HTA6IsoHwv #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech
— Dr Timos Papagatsias (@_timos_) July 18, 2020
The Global Vaccines Market Growth & Major Players – Astellas , CSL, Johnson & Johnson https://t.co/CV4KYxOA1i #VaccinesMarket #GlobalVaccinesMarket #VaccinesMarketSize #VaccinesMarketShare #VaccinesMarketTrends #VaccinesMarketGrowth #VaccinesMarketFuture #Vaccines
— Kriti Singh (@KritiSi62917720) May 30, 2019
Key players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), MedImmune, LLC… https://t.co/ZZYfSHHK27
— PressRelease.cc (@PressRelease_cc) October 28, 2019
CSL is proud 2 announce that Dr. Bill Carson, CEO of Otsuka Pharma. Development & Commercialization joined our advisory team @elginthompson
— Culture Shift Labs (@CultureShiftLab) March 27, 2014
United States Influenza Vaccines Market 2018-2025 Analysis by emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca https://t.co/qQqrKL10Fm via @openPR
— DPI Research_Vaccine (@MarketR_Vaccine) November 5, 2018
Participants at the Asia Pacific and Japan Society of Hemostasis and Thrombosis conference shared perspectives on advances in #Haemophilia management, discussing options for individualised treatment #patientpromise pic.twitter.com/vJSgDfKyFh
— CSL (@CSL) July 9, 2018
To mark #WorldHaemophiliaDay, our colleagues in Japan share their heartfelt messages of support for the bleeding disorders community and demonstrate how we are driven everyday by our promise to patients. pic.twitter.com/CPGbZ7ULYj
— CSL (@CSL) April 17, 2018
Take a video tour of our new #CSLBehring office in Tokyo, #Japan. https://t.co/4mKVDWT1i6 pic.twitter.com/gPArofSVwx
— CSL Behring (@CSLBehring) July 15, 2019
We’re proud to bring 2 new options to #CIDP patients in Japan. https://t.co/HYxworDI6U pic.twitter.com/NCclP5p9ce
— CSL Behring (@CSLBehring) April 4, 2019
Our team in #Japan recently painted traditional Shisa sculptures as they reflected on past accomplishments and looked ahead to the future. pic.twitter.com/zOKXX5qCkG
— CSL Behring (@CSLBehring) August 9, 2017
Thank you to all – especially those in our Tokyo office – who helped bring our first #hemophilia product to Japan. https://t.co/MICGBFKdPg pic.twitter.com/gYYJpKe4fz
— CSL Behring (@CSLBehring) September 30, 2016
We're proud to bring our first #hemophilia product to Japan. https://t.co/sWn3BoCY3G pic.twitter.com/L6WvlTra6i
— CSL Behring (@CSLBehring) September 30, 2016
Our colleagues around the world took the #RedTieChallenge to support patients who have bleeding disorders. Japan! pic.twitter.com/Zdzm1PwMII
— CSL Behring (@CSLBehring) April 22, 2016
Despite the low awareness of patient groups in #Japan, healthcare professionals recognise the potential of patient representation in the #rarediseases space > https://t.co/bZIBH7dX3m via @CSLBehring pic.twitter.com/JcG4QtBbxy
— The Economist Intelligence Unit (@TheEIU) August 12, 2020
“Global biotherapeutics leader CSL Behring recently announced that Japan's Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with CIDP” https://t.co/jXmvuFEow5 pic.twitter.com/0J9uW53K2u
— CIDP Neuropathy (@CIDPNeuropathy) April 2, 2019
Japan Approves Berinert from @CSLBehring for Short-Term Prophylactic Treatment of HAE: https://t.co/6mZE48U2hd
— HAE International (HAEi) (@HAEDAY) March 24, 2017
CSL Behring's long-acting hemophilia B treatment Idelvion approved in Japan https://t.co/RsklhGEDr2 $QURE $ONCE $NVO $BAX
— Breaking News (@MarketCurrents) September 29, 2016
Takeda, Moderna partner up to bring 50M coronavirus shots to Japan | @TakedaPharma @Moderna_tx @Novavax @CSLBehring #Covid19 #Biotech #Vaccine #Deerfield #Cambridge #Massachusetts #Rockville #Maryland https://t.co/rP1SGKCnO9
— Pharm2Market (@pharm2market) October 31, 2020
